Welcome to my homepage



1. Nagayama Y. TSH Receptor (Thyrotropin Receptor). Reference Module in Biomedical Sciences. Elsevier. 10-Apr-2017 doi:10.1016/B978-0-12-801238-3.96039-2.
2. Shimamura M, Kurashige T, Mitsutake N, Nagayama Y. Aldehyde dehydrogenase activity plays no functional role in stem cell-like properties in anaplastic thyroid cancer cell lines. Endocrine. 55 (3): 934-943, 2017.
3. Kurashige T, Shimamura M, Nagayama Y. N-acetyl-L-cysteine protects thyroid cells against DNA damage induced by external and internal irradiation. Radiat Environ Biophys. 56 (4): 405-412, 2017.
1. Nagayama Y, Shimamura M, Mitsutake N. Cancer stem cells in the thyroid. Frontiers in Endocrinology, section Thyroid Endocrinology. 7:20, 2016.
2. Kurashige T, Shimamura M, Nagayama Y. Differences in quantification of DNA double strand breaks between 53BP1/gammaH2AX focus formation assays and the comet assay in mammalian cells treated with irradiation and N-acetyl-L-cysteine. J Radiat Res. 57 (3): 312-317, 2016.
3. Nikitski A, Saenko V, Shimamura M, Nakashima M, Matsuse M, Suzuki K, Rogounovitch T, Bogdanova T, Shibusawa N, Yamada M, Nagayama Y, Yamashita S, Mitsutake N. Targeted Foxe1 overexpression in mouse thyroid causes the development of multinodular goiter but does not induce carcinogenesis. Endocrinology. 157(5):2182-2195, 2016.
1. Kurashige T, Shimamura M, Yasui K, Mitsutake N, Matsuse M, Nakashima M, Minami S, Eguchi S, Nagayama Y. Expression of aldehyde dehydrogenase in normal and cancerous tissues of thyroids. Horm Metab Res.47 (3): 194-199, 2015.
2. Jia N, Nakazawa Y, Guo C, Shimada M, Sethi M, Takahashi Y, Ueda H, Nagayama Y, Ogi T. A rapid, comprehensive system for assaying DNA repair activity and cytotoxic effects of DNA-damaging reagents. Nat Protcol. 10(1):12-24, 2015.
3. Nakashima M, Shimamura M, Yasui K, Mitsutake N, Matsuu-Matsuyama M, Matsuda K, Nagayama Y. Cancer stem cell theory and intratumor heterogeneity in thyroid carcinogenesis. J Basic Clin Med. 4(1): 8-12, 2015.
4. Nagayama Y, Nakahara M, Abiru N. Animal models of Graves’ disease and Graves’ orbitopathy. Curr Opin Endocrinol Diabetes Obes. 22 (5): 381-386. 2015.
5. Akazawa S, Kobayashi K, Kuriya G, Horie I, Yu L, Yamasaki H, Okita M,Nagayama Y, Matsuyama T, Akbari M, Yui K, Kawakami A, Abiru N. Haploinsufficiency of interferon regulatory factor 4 strongly protects against autoimmune diabetes in non-obese diabetic mice. Diabetologia, 58 (11): 2606-2014. 2015.
6. Matsuu-Matsuyama M, Shichijo K, Okaichi K, Kurashige T, Kondo H, Miura S, Nakashima M.Effect of age on the sensitivity of the rat thyroid gland to ionizing radiation.J Radiat Res. 56(3):493-501, 2015.
7. Miura S, Akazawa Y, Kurashige T, Tukasaki K, Kondo H, Yokota K, Mine M, Miyazaki Y, Sekine I, Nakashima M.The Nagasaki Atomic Bomb Survivors' Tumor Tissue Bank. Lancet. 2015 386(10005):1738, 2015.
1. Orim F, Bychkov A, Shimamura M, Nakashima M, Mito M, Bogdanova T, Matsuse M, Suzuki K, Saenko V, Nagayama Y, Yamashita S, Mitsutake N. Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAFV600E-induced thyroid tumors in a mice model. Thyroid. 24(3):502-510, 2014.
2. Shimamura M, Nakahara M, Kurashige T, Yasui K, Nakashima M, Nagayama Y. Disruption of transforming growth factor-b signaling in thyroid follicular epithelial cells or intrathyroidal fibroblasts does not promote thyroid carcinogenesis. Endocrine J. 61(3):297-302, 2014.
3. Shimamura M, Nagayama Y, Matsuse M, Yamashita S, Mitsutake N. Analysis of multiple markers for cancer stem-like cells in human thyroid carcinoma cell lines. Endocrine J. 61 (15): 481-490, 2014.
4. Yasui J, Nakahara M, Shimamura M, Kurashige T, Yasui K, Abiru N, Kawakami A, Nagayama Y. Minor contribution of cytotoxic T lymphocyte antigen 4 and programmed cell death 1 ligand 1 in immune tolerance against mouse thyrotropin receptor in mice. Acta Med Nagasaki. 59 (1): 13-17, 2014.
1. Johnson KTM, Ziler B, Schott M, Muller M, Minich WB, Nagayama Y, Gulbins E, Eckstein AK, Berchner-Pfannschmidt U. Examination of Orbital Tissues in Murine Models of Graves' Disease reveals expression of UCP-1 and the TSHR in retrobulbar adipose tissues. Hor Metb Res. 45 (6): 401-407, 2013.
2. Kobayashi M, Kaneko-koike C, Abiru N, Uchida T, Akazawa S, Nakamura K, Kuriya G, Satoh T, Ida H, Kawasaki E, Yamasaki H, Nagayama Y, Sasak H, Kawakami A. Genetic deletion of Granzyme B does not confer resistance to the development of spontaneous diabetes in NOD mice. Clin Exp Immunol. 173 (3):411-418,2013.
3. Kashiyama K, Nakazawa Y, Shimada M, Sasaki K, Takahashi Y, Fawxett H, Lewin SO, Carr L, Yoshida K, Utani A, Hirano A, Yamashita S, Nagayama Y, Mitsutake N, Lehmann AR, Ogi T. Identification of new Cockayne syndrome patients deficient in the ERCC1 and XPF/ERCC4 gene. Am J Hum Gnenet. 92 (5):807-819, 2013.
4. Kuriya G, Abiru N, Kobayashi M, Nagayama Y, Akazawa S, Nakamura K, Sato T, Horie I, Kuwahara H, Kawasaki E, Yamasaki H, Yu L, Eisenbarth GS, Iwakura Y, Eguchi K. Double deficiency in IL-17 and IFN-g signaling significantly suppresses the development of diabetes in the NOD mouse. Diabetologia. 56 (8):1773-1780, 2013.
5.Yasui K, Shimamura M, Mitsutake N, Nagayama Y. SNAIL Induces Epithelial-to-Mesenchymal Transition but not Cancer Stem Cell-like Properties in Thyroid Cancer. Thyroid. 23 (8):989-996, 2013.
1. Nagayama Y, Nakahara M, Shimamura M, Horie I, Arima K, Abiru N. Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism in mice. Clin Exp Immunol.168 (3): 268-273, 2012.
2. Nakahara M, Johnson K, Eckstein A, Yamada N, Taguchi R, Abiru N, Nagayama Y. Adoptive transfer of antithyrotropin receptor (TSHR) autoimmunity from TSHR knockout mice to athymic nude mice. Endocrinology. 153 (4): 2034-2042, 2012.
1. Nagayama Y. Animal models of autoimmune thyroid disease. (In) Immunoendocrinology: Scientific and Clinical Aspects. Eisenbarth G (ed), Humana Press, pp.415-426, 2011.
2. Taira Y, Hayashida N, Brahmanandhan GM, Nagayama Y, Yamashita S, Takahashi J, Gutevitc A, Kozlovsky A, Urazalin M, Takamura N. Current concentration of artificial radionuclides and estimated radiation doses around the Chernobyl Nuclear Power Plant, the Semipalatinsk Nuclear Testing Site, and in Nagasaki. J Radiat Res. 52 (1): 88-95, 2011.
3. Ueki I, Abiru N, Kobayashi M, Nakahara M, Ichikawa T, Kerley, Eguchi K, Nagayama Y. B Cell-Targeted Therapy with anti-CD20 monoclonal antibody in a mouse model of Graves’ Hyperthyroidism. Clin Exp Immunol. 163(3):309-317, 2011.
4. Horie I, Abiru N, Saitoh O, Ichikawa T, Iwakura Y, Eguchi K, Nagayama Y. Distinct role of T helper type 17 immune response for Graves’ hyperthyroidism in mice with distinct genetic backgrounds. Autoimmunity. 44(2):159-165, 2011.
5. Suzuki K, Mitsutake N, Saenko V, Matsuse M, Ohtsuru A, Kumagai A, Uga T, Yano H, Nagayama Y, Yamashita S. Dedifferentiation of human primary thyrocytes into multilineage progenitor cells without gene introduction. PLoS ONE. 6(4) : e19354, 2011.
6. Ueki I, Abiru N, Kawagoe K, Nagayama Y. IL-10 deficiency attenuates induction of anti-thyrotropin receptor antibodies and hyperthyroidism in a mouse Graves’ model. J Endocrinol. 209 (3): 353-357, 2011.
7. Nakahara M, Nagayama Y, Ichikawa T, Liping Yu, George S. Eisenbarth, Abiru N. The effect of Regulatory T cell depletion on the spectrum of organ-specific autoimmune diseases in non-obese diabetic mice at different ages. Autoimmunity. 44 (6): 504-510, 2011.
8. Horie I, Abiru N, Sakamoto H, Iwakura Y, Nagayama Y. Induction of autoimmune thyroiditis by depletion of CD4+CD25+ regulatory T cells in thyroiditis-resistant IL-17, but not interferon-gamma receptor, knockout nonobese diabetic-H2h4 mice. Endocrinology. 152 (11): 4448-4454, 2011.
9. Satoh T, Abiru N, Kobayashi M, Zhou H, Nakamura K, Kuriya G, Nagayama Y, Kawasaki E, Yamasaki H, Yu L, Eisenbarth GS, Araki E, Mori M, Oyadomari S, Eguchi K. CHOP deletion does not impact the development of diabetes but suppresses the early production of insulin autoantibody in the NOD mouse. Apoptosis. 16 (4): 438-448, 2011.
1. Nagayama Y. Observations on the proposed “nonclassical” model of autoimmune hypothyroidism. Thyroid. 20 (6): 665-666, 2010.
2. Nakahara M, Mitsutake N, Sakamoto H, Ichiakwa T, Abiru N, Chen C-R, Rapoport B, McLachlan SM, Nagayama Y. Enhanced response to mouse thyrotropin (TSH) receptor immunization in TSH knockout mice. Endocrinology. 151 (8): 4047-4054, 2010.
3. Chen C-R, Hamidi S, Braley-Mullen H, Nagayama Y, Bresee CMS, Rapoport B, McLachlan SM. Antibodies to thyroid peroxidase arise spontaneously with age in NOD.H-2h4 mice but are not associated with experimentally induced thyroiditis. Endocrinology. 151 (9): 4583-4593, 2010.


1. Nagayama Y. Animal models of autoimmune thyroid disease. (In) Immunoendocrinology. Eisenbarth G (ed), in press, 2010.
1. Nagayama Y. TSH receptor (thyrotropin receptor). (In) The Encyclopedia of Endocrine Diseases. Martini L. (ed) Academic Press. Vol. 4, 632-635, 2004.
2. Nagayama Y. Gene Therapy for thyroid cancer. (In) Molecular Basis of Thyroid Cancer. Farid NR. (ed) Kluwar Academic Pub. 369-379, 2004.
1. Nagayama Y. The Thyroid stimulating hormone receptor. (In) Thyroid Eye Disease: Diagnosis and Treatment. Dutton JJ and Haik BG (ed), 19-27, 2002.